With traditional taboos receding, and the biotechnology and pharmaceutical sectors in flux, some researchers are moving from industry back to academia. Quirin Schiermeier looks at the trade-offs.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Related external links
University of Dundee drug discovery unit
Rights and permissions
About this article
Cite this article
Schiermeier, Q. The way back. Nature 466, 402–403 (2010). https://doi.org/10.1038/nj7304-402a
Published:
Issue Date:
DOI: https://doi.org/10.1038/nj7304-402a
